Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We will walk you through the key developments from the third quarter, after which we will be happy to answer any questions you may have. Our lead asset, linaprazan glurate, is the next-generation PCAB that offers sustained around-the-clock acid control that distinguishes it from the rest. From both PPIs and all other PCABs in severe erosive GERD. The patient population we are addressing is large and underserved. Roughly 10 million people across the US and Europe live with severe erosive GERD, and globally, 19 million, with a substantial share of them not adequately healed by today's standard of care. This makes this a specialist-driven commercial opportunity rather than a primary care one. Superior acid control translates directly into better healing, faster healing, and better symptom control, which will give us a clinically and commercially differentiated product. Our Phase III program began in September 2025, and I am pleased to report that HEEALING1 is now complete with 523 patients randomized, exceeding the protocol-specified target of 501 patients, and all planned patient visits were completed in September.
As we have communicated earlier, HEEALING1 topline results are expected this quarter, which of course could be a major value inflection point for Cinclus Pharma. The program continues to be well de-risked at this stage; we have a robust clinical data package and alignment from both FDA and EMA on our regulatory strategy. And we also have a well-defined CMC plan. We see that the first-generation PCABs are rapidly gaining traction. PCABs are now available in more than 30 countries, and local treatment guidelines are incorporating PCABs into the treatment recommendations. It's clear that PCABs are about to take over the market from the current standard of care treatment with PPIs. Linaprazan glurate has been launched in China in 2026 by Huadong, the commercialization partner of our license partner, Sinorda. The launch has achieved broad coverage across Chinese markets with a significant increase in sales volume compared with the previous quarter. The third quarter marked the completion of several important milestones for HEEALING1, and in July, we reached the study randomization target. In September, the final patient completed the eight-week treatment period, followed later that month by the final safety follow-up visit, completing all planned patient visits in the study after the end of the quarter. Results from the Phase I studies of Linaprazan glurate were published in Alimentary Pharmacology and Therapeutics. The studies demonstrated rapid and sustained acid control with close to 100% pH control at the highest dose levels. Okay, let's go into the HEEALING1 study. Let me provide an update on the HEEALING1 study as we approach the topline readout. Exciting times. So, a total of 523 patients from eight European countries were randomized into HEEALING1, exceeding our protocol-specified target of 501 patients. All planned patient visits in the study have been completed. The study has progressed on schedule with rapid patient recruitment, which highlights the substantial unmet medical need and demand for more effective treatment of erosive GERD. The primary endpoint is superiority to lansoprazole in healing of severe erosive GERD.
Of the patients with grade C and D, the severe patients, this should be done after four weeks of treatment. Key secondary endpoints cover healing and symptom relief through four and eight weeks for both the severe patients and the full intent-to-treat population, but also for all patients including grades A, B, C, and D. HEEALING2.
Our second and final Phase III study will evaluate patients suffering from erosive GERD with acute and maintenance therapy at clinical sites in Europe, the EU, and the US. It is planned to initiate following HEEALING1 topline results during June 2027. We are anticipating topline results from the HEEALING1 study this quarter, as we have previously stated, with a good margin before the holiday season in late December. Okay, let's look into the 24-hour acid control. You have seen this chart before, but it is a very important one. The relation between acid control and healing is well established. It is a biomarker. The greater the percentage of time that gastric pH is maintained above four, the higher the healing rate. This is particularly important in severe erosive GERD, where prolonged exposure to gastric acid damages the lining of the esophagus, and effective acid suppression is critical to enable healing. This slide illustrates the number of hours that pH in the stomach is below four, with different treatment alternatives. If we start from the left with the old H2 blockers such as Zantac that were launched during the 70s, pH was below four during approximately 16 hours. Still, they became the most sold drugs in the world and were very successful. The pH below four was reduced to seven to 14 hours. With the introduction of PPIs, which you also know about, they became a huge commercial success. And then we have the first-generation PCAB launches, such as vonoprazan and tegoprazan. They have reduced the time below pH 4. The time below pH 4 is reduced to 4 to 7 hours. Our studies show that Linaprazan glurate pH is below four for only one hour per day. A major improvement to all existing treatment alternatives, highlighting a best-in-class profile with significant market potential. A sustained acid control profile is particularly relevant for patients with severe erosive GERD, where achieving sufficient acid suppression remains an important unmet need. This slide brings together the pharmacologic and clinical profile we have discussed. In the table to the left, you can see that linaprazan glurate has the highest level of 24-hour acid control reported for any other drug in both PPI and PCAB classes. You can also see that Linaprazan glurate has a quicker time to reach a pH above four and the full effect after the first dose, which is in contrast to what you see with PPIs and Vonoprazan. Also seen to the right. Thanks to these advantages. No disadvantages are apparent. To the left. The ambition is now to show that linaprazan glurate offers, in comparison to PPIs, better healing, faster healing, half the time to full healing, and better symptom relief compared to what you have seen with other PCABs. So that is, in a nutshell, what we mean when we describe linaprazan glurate as a next-generation PCAB with a best-in-class profile.
So let's turn to Magnus to review our financial results for the quarter. Please go ahead, Magnus.